EP1144434A2 - Combinatorial process for preparing polyamines - Google Patents

Combinatorial process for preparing polyamines

Info

Publication number
EP1144434A2
EP1144434A2 EP99936759A EP99936759A EP1144434A2 EP 1144434 A2 EP1144434 A2 EP 1144434A2 EP 99936759 A EP99936759 A EP 99936759A EP 99936759 A EP99936759 A EP 99936759A EP 1144434 A2 EP1144434 A2 EP 1144434A2
Authority
EP
European Patent Office
Prior art keywords
group
moiety
formula
process according
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99936759A
Other languages
German (de)
French (fr)
Other versions
EP1144434A3 (en
Inventor
Lloyd James Payne
Neal David Hone
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Pharmaceuticals Ltd
Original Assignee
Millennium Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/GB1998/003775 external-priority patent/WO1999031049A1/en
Application filed by Millennium Pharmaceuticals Ltd filed Critical Millennium Pharmaceuticals Ltd
Publication of EP1144434A2 publication Critical patent/EP1144434A2/en
Publication of EP1144434A3 publication Critical patent/EP1144434A3/en
Withdrawn legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06086Dipeptides with the first amino acid being basic
    • C07K5/06095Arg-amino acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/047Simultaneous synthesis of different peptide species; Peptide libraries

Definitions

  • This invention relates to a process for preparing polyamines and particularly, although not exclusively, relates to a solid phase process and/or a process which can readily be used in a combinatorial or parallel array technique-
  • polyamine amide compounds have shown neurological activity and have glutamate receptor antagonist activity. Hitherto, they have been considered for use in the treatment of neurological disorders such as Alzheimer's disease, Huntingdon's chorea, stroke and brain trauma.
  • a process for preparing a polyamine compound which includes a step (a) of treating a compound which incorporates a moiety of formula:
  • SS represents a solid support and linking means for linking the group -NR- of moiety I to the support
  • R represents a hydrogen atom or an optionally-substituted alkyl or aryl group
  • R 1 represents a hydrogen atom or an optionally-substituted alkyl or aryl group
  • R b and R c each independently represents an optionally-substituted alkylene or alkenylene group
  • L represents a leaving group.
  • any group may be substituted by one or more substituents.
  • it may be substituted by up to 4, preferably up to 3, more preferably up to 2, especially up to 1 substituent.
  • optional substituents may be selected from halogen (preferably fluorine, chlorine or bromine) atoms and optionally substituted, preferably unsubstituted, alkyl, acyl, aryl, nitro, cyano, alkoxy, alkoxyalkyl, hydroxy, amino, alkylamino (including dialkylamino) , sulphinyl, alkylsulphinyl, carbamoyl (including alkylcarbamoyl and dialkylcarbamoyl) , sulphonyl, alkylsulphonyl, sulphonate, amido, alkylamido, alkoxycarbonyl, halocarbonyl (especially chlorocarbonyl) , haloalkoxy, and haloalkyl (especially fluoroalkyl or chloroalkyl) , groups.
  • halogen preferably fluorine, chlorine or bromine
  • an alkyl, alkenyl, alkylene or alkenylene group may have up to 12, suitably up to 10, preferably up to 8, more preferably up to 6, especially up to 4, carbon atoms.
  • an aryl group is suitably an aromatic or heteroaromatic group which preferably has 6 to 10 ring atoms and, more preferably, has 6 or 10 ring atoms.
  • aromatic groups include phenyl, 1-naphthyl and 2-naphthyl groups of which the phenyl group is preferred.
  • Heteroaromatic groups may include one or more 0, N or S atoms or combinations thereof.
  • the process suitably produces a compound which incorporates a moiety: WO 00/35941 _- ⁇ 4 _- PCT/GB99/01719
  • R represents a hydrogen atom or an optionally-substituted, preferably an unsubstituted, alkyl group. More preferably, R represent a hydrogen atom.
  • R b and R c may independently have up to 10, suitably up to 8, preferably up to 6, more preferably up to 4, carbon atoms in a straight chain.
  • R b and R c may have the same number of carbon atoms in a straight chain in which case compounds which include moiety III (and compounds moieties produced in downstream processes) may be symmetrical polyamines.
  • R b and R c may have a different number of carbon atoms in a straight chain in which case compounds which include moiety III (and compounds/moieties produced in downstream processes) may be unsymmetrical polyamines.
  • Unsymmetrical polyamines can be quite difficult to prepare by known processes; however, the process described herein can relatively easily be used to make such compounds.
  • R and R c independently have 3 or 4 carbon atoms in a straight chain. More preferably, R c has 4 carbon atoms and R b has 3 carbon atoms in a straight chain. R b and R c may independently be optionally substituted by 1 or 2 optionally-substituted, preferably unsubstituted, alkyl groups, wherein each alkyl group suitably has 1 to 3 carbon atoms.
  • R 1 suitably represents a hydrogen atom or a C ⁇ - ⁇ o, preferably C ⁇ - 8 , more preferably C ⁇ _ 6 , especially C ⁇ - 4 , alkyl group or an aryl group, said alkyl or aryl group being optionally-substituted, preferably by one or more substituents selected from halogen atoms, amino groups, alkylamino groups, dialkylamino groups, cyano groups, hydroxy groups, alkyl groups (except when the substituted group is alkyl) , aryl groups, carbamoyl groups, alkylcarbamoyl groups, dialkylcarbamoyl groups and carboxy groups and esters thereof.
  • R 1 represents a hydrogen atom or an optionally-substituted, preferably an unsubstituted, alkyl or aryl group.
  • R 1 represents a hydrogen atom or an optionally-substituted alkyl group.
  • P 1 represents a protecting/activating group.
  • P 1 is preferably an electron-withdrawing group. It is preferably adapted to increase the acidity of the hydrogen atom of the group -NHP 1 .
  • P 1 preferably forms a sulphonamide group with moiety I.
  • P 1 preferably represents a moiety: -SO2-X 1 V
  • X 1 represents an optionally-substituted aryl, especially phenyl, group.
  • Said optionally-substituted aryl group may include one or more substituents.
  • Preferred substituents are electron-withdrawing groups.
  • a nitro group is a preferred optional substituent.
  • a 4- nitro or a 2,4-nitro is especially preferred.
  • X 1 represents a di-nitrophenyl group.
  • moieties I and II The mechanism of the reaction of moieties I and II is believed to involve attack of the nucleophilic nitrogen atom of moiety -NH- of moiety I with a carbon atom adjacent to leaving group L in moiety II.
  • L is preferably an electron-withdrawing group. Consequently, the leaving group L is displaced.
  • L may need to be activated to act as a leaving group in the reaction.
  • L may be any leaving group which may be electronegative and/or be capable of functioning in the mechanism referred to.
  • L may be a halogen atom, preferably a bromine or chlorine atom, especially a bromine atom, or a hydroxy group. The ability of the hydroxy group to act as a leaving group may be caused and/or enhanced by other reagents used in the reaction.
  • P 2 NR X -R b -L VI wherein P 2 represents a protecting group.
  • Preferred protecting groups include N-l- (4, 4-dimethyl-2, 6- dioxocyclohex-1-ylidene) ethyl and Triethlsilyloxycarbonyl (TEOC) . The former is preferred.
  • SS represents a solid support resin which includes linking means.
  • Said linking means may include a -O-CO- moiety, the carboxy end of which is suitably bonded to the nitrogen atom of the moiety -NR- of moiety I.
  • the alkoxy end of the -0-CO- moiety may be bonded to the resin by suitable means which is preferably an alkylene group, especially a -CH 2 - group.
  • Said solid support resin may be any suitable resin, for example a polystyrene resin.
  • the linking means is a Wang linker.
  • Step (a) swollen resin of formula I (which may suitably be swollen in anhydrous tetrahydrofuran) , triphenylphosphine and a said compound which incorporates moiety II (especially compound VI) may be stirred together and, subsequently, a coupling agent, suitably diethylazodicarboxylate, is added, slowly. The mixture may be stirred for about 12 hours, filtered, washed and dried.
  • the product of the reaction suitably incorporates moiety III and is suitably protected by groups P 2 and P 1 and is, therefore, of formula:
  • Said compound VI may be prepared by a reaction known to a person skilled in the art, wherein P 2 is a protecting group.
  • Said compound IV may be prepared in a step (-b) which comprises reaction of a compound of general formula:
  • reaction is preferably carried out in the presence of a base, for example 2,6-lutidine and in an organic solvent.
  • Said compound of formula VIII may be prepared in a step (-c) by reaction of a compound of formula
  • L 3 represents a leaving group which may include an imidazole moiety.
  • Compound VII and/or said compound incorporating moiety II can readily be derivatised to produce a wide range of compounds, suitably in a parallel array or combinatorial chemistry technique.
  • compound VII and/or said compound incorporating moiety III may be treated with a further compound which incorporates a moiety of formula II (which moiety may include R 1 , R b and L which are the same as or different to such groups used in Step (a) ) as described above thereby to prepare a compound which incorporates the moiety
  • R b (2), R x (2) and P 2 (2) may be any group described herein for R b , R 1 and P 2 respectively except that they may be the same or different to groups R b and R 1 used in Step (a) and P 2 as described above.
  • said compound of formula VII may be reacted to remove P 1 and replace it with, for example another protecting group (e.g. Boc) and P 2 may be removed and replaced with a protecting/activating group of type P 1 discussed above.
  • the derivatised compound VII prepared may then be treated, for example with a structure of formula:
  • the derivatisation of the first embodiment may be further repeated to add successive groups -NR 1 (3) -R b (3) - etc.
  • Compound VII may be derivatized by a range of compounds, for example amino acids, may be coupled to moiety -NR 1 - (or -NR 1 (2), -NR 1 (3) if provided) , thereby replacing protecting group P 2 and, in turn, other compounds, for example further amino acids, may be coupled to said compounds initially coupled to moiety -NR 1 - (or -NR 1 (2), -NR 1 (3), if provided) and/or derivatisation reactions effected. Further coupling reactions may also be effected by techniques known to those skilled in the art.
  • a suitably deprotected compound VII and/or said compound incorporating moiety III may be treated with a first reagent (which may be protected) to replace group P 2 in compound VII with a residue of said first reagent.
  • the product (or a derivative), suitably deprotected may be treated with a second reagent (which may be protected) so that said second reagent becomes bonded to a said residue of said second reagent.
  • Such treatments may be repeated to react further reagents with the derivative of compound VII.
  • said first reagent is di-functional.
  • Said first reagent preferably includes an aryl group (or a precursor thereof) .
  • Said first reagent preferably includes an amine group (or a precursor thereof) .
  • said first reagent (and a or any subsequent reagent) is an amino acid (or a precursor thereof, for example a protected version or derivative thereof) .
  • said second reagent is di-functional.
  • Said second reagent preferably includes an aryl group (or a precursor thereof) .
  • Said second reagent preferably includes an amine group (or a precursor thereof) .
  • said second reagent is an amino acid (or a precursor thereof, for example a protected version or derivative thereof) .
  • Further reagents which may be reacted with said second reagent may have any feature of said second reagent as described above.
  • step (b) said compound of formula VII may be reacted in a step (b) to substitute the group P 1 with another group which may be another protecting group P 3 or an electrophilic reagent.
  • Group P 3 may be an acyl, -Boc, alkyl, or sulphonyl group.
  • the product of step (b) may be a compound of formula
  • Step (c) may involve reaction in hydrazine and an organic solvent or may involve any suitable deprotection reaction.
  • a compound may be coupled to the free -NH 2 group of compound XI.
  • an amino acid suitably an amino acid which is protected by a protecting group orthogonal to the group binding portions of compound X to the solid support of SS, such as an Fmoc protected amino acid (i.e. "Fmoc AA"
  • an amino acid selected from those shown in Summary 1 or Summary 2 hereinafter, especially those in Summary 1 may be coupled to said group.
  • other compounds for example other amino acids, may be coupled, for example to the aforementioned amino acid, in order to produce more complex compounds using procedures know to those skilled in the art.
  • an amino acid selected from those shown in Summary 1 or Summary 2 hereinafter, especially those in Summary 2 may be coupled.
  • the desired compound prepared may be cleaved from the resin and/or optionally derivatised as may be desired.
  • Such a compound may incorporate a moiety
  • a 1 is a substituent group which may comprise one or more optionally derivatised amino acid residues or is a salt of the aforementioned compound.
  • such a compound may be of formula
  • R, R c , R b and R 1 are as described in any statement herein;
  • W is a hydrogen atom or an optionally- substituted, preferably unsubstituted, alkyl or aryl group;
  • Z is an amino acid residue, especially an aromatic amino acid residue;
  • n is zero or a positive integer, preferably in the range 0-10, more preferably 0-4, especially 0 to 1;
  • R 2 and R 3 are the same or different from each other and each represents a hydrogen atom or a group of formula R 6 , R 6 CO-, R 6 OCO- or R 6 NHCO- where R 6 represents an optionally-substituted alkyl group, suitably a Ci-io, preferably a Ci-e, more preferably a Ci- ⁇ , especially a C ⁇ - , alkyl group, or an optionally- substituted aryl group, wherein preferred optional substituents of said alkyl and aryl groups are selected from halogen atoms, amino groups
  • a process for preparing a plurality of different polyamine compounds which includes a step of:
  • a library of compounds prepared in a process according to said second aspect.
  • the resin was again swollen in dichloromethane (1.0 ml), and di-t-butyl dicarbonate (10 equivalents, 0.3 mmol, 33 mg) and N,N-dimethylaminopyridine (5 mol%, 0.0015 mmol, 0.2 mg) were added, and the mixture was stirred for 16 hours. The resin was then filtered and washed (dimethylformamide, methanol, dichloromethane) , and then dried in vacuo.
  • the resin was then stirred in 2% hydrazine hydrate/dimethylformamide (1.0 ml) for 1 hour and then washed (dimethylformamide, methanol, dichloromethane) , after which it was dried in vacuo.
  • Boc-Arg(Pbf) -OH (4 equivalents, 0.12 mmol, 63 mg)
  • TBTU (4 equivalents, 0.12 mmol, 39 mg)
  • diisopropylethylamine 8 equivalents, 0.48 mmol, 62 mg
  • the Dde protected aminoalcohol was prepared as follows: To a solution of 3-amino-l-propanol (1.5 g, 20 mmol) in ethanol was added 2-acetyl dimedone (1.1 equivalents, 22 mmol, 4.0 g) and the mixture was heated to
  • the resin was again swollen in DCM (1.0 ml) and di-t- butyldicarbonate (10 eq, 0.3 mmol) and N,N- dimethylaminopyridine (5 mol%, 0.0015 mmol) added and the mixture stirred for 16 hours.
  • the resin was then filtered and washed (DMF, MeOH, DCM) then dried in vacuo.
  • the resin was then stirred in 2% hydrazine hydrate/DMF (1.0 ml) for 1 hour then washed (DMF, MeOH, DCM) and dried in vacuo.
  • Fmoc AA1 The Fmoc derivatives of the amino acids shown in Summary 1 (wherein residues thereof are destined to become Portion 1 in the polyamines) were prepared (hereinafter referred to, generally, as "Fmoc AA1") . Then, Fmoc AA1 (4 eq, 0.12 mmol), TBTU (4 eq, 0.12 mmol) and diisopropylethylamine (8 eq, 0.48 mmol) were dissolved in anhydrous DMF (1.0 ml) and the mixture added to the resin. The whole was then stirred for 12 hours then filtered and washed (DMF, MeOH, DCM) and dried in vacuo.
  • Boc AA eq, 0.12 mmol
  • TBTU eq, 0.12 mmol
  • diisopropylethylamine 8 eq, 0.48 mmol
  • amino acid residues incorporated into compound E-I comprise the amino acids shown in Summary I and II but excluding hydrogen atoms from the -NH 2 and -C0 2 H groups.
  • Table 1 summarises a 4, 4-polyamine library prepared - that is, a library wherein n and m represent 4; the left column in the table details respective Portion l's (identified by their letters in Summary 1) used to prepare the compounds; and the top row details respective Portion 2's (identified by their numbers in Summary 2) used to prepare the compounds.
  • Table 2 summarises a 3, 4-polyamine library - that is, wherein n represents 3 and m represents 4 with Portions 1 and 2 being identified as before.
  • each box in the table represents a particular compound prepared and the Mass Spec (ES + ) and HPLC Retention Time in minutes are provided in each box (where available) .
  • TEOC may be used.
  • Derivatives of the amines prepared in Examples 1 and 2 may be prepared by reaction with a compound having an electrophilic specie such as an acid chloride, sulphonyl chloride etc.
  • the starting material of Step 5 may be acylated, instead of using di-t- butyldicarbonate to give a Boc protecting group.
  • Acylation may be carried out using a standard technique, using an acid chloride or another activated acid, to produce peptidomimetics .
  • Sulphonyl chlorides may be used to sulphonylate amine groups to produce derivatives.
  • Step 4 in Example 4 may be repeated more than once in order to add further moieties -NH-(CH 2 ) n - to the polyamine chain.
  • the Dde group may be removed and the resultant free amine group re-sulphonated in a process analogous to that described in Step 3.
  • the re-sulphonated product may then be treated with a Dde-protected amine alcohol in a process analogous to that described in Step 4.
  • Step 5 may be repeated.
  • further moieties -NH-(CH 2 ) n - may be added in the manner described or Step 6 and subsequent steps described may be carried out.
  • the product of Step 6 may be of formula
  • N is an integer of 1 or greater and wherein n may be the same or different for each repeat unit N.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

A process for preparing polyamines of, for example, formula (A) includes a step (a) of treating a compound which incorporates a moiety of formula: (I) SS-NR-Rc-NH- with a compound which incorporates a moiety of formula: (II) -NR1-Rb-L and optionally derivatising the product of the reaction, wherein SS represents a solid support and linking means for linking the group -NR- of moiety (I) to the support, R represents a hydrogen atom or an optionally-substituted alkyl or aryl group, R1 represents a hydrogen atom or an optionally-substituted alkyl or aryl group, R?b and Rc¿ each independently represents an optionally-substituted alkylene or alkenylene group and L represents a leaving group and wherein A1 is a substituent group.

Description

PROCESS FOR PREPARING POLYAMINES
This invention relates to a process for preparing polyamines and particularly, although not exclusively, relates to a solid phase process and/or a process which can readily be used in a combinatorial or parallel array technique-
Several naturally occurring polyamine amide compounds have shown neurological activity and have glutamate receptor antagonist activity. Hitherto, they have been considered for use in the treatment of neurological disorders such as Alzheimer's disease, Huntingdon's chorea, stroke and brain trauma.
Traditionally, the compounds have been isolated from natural sources such as spider and wasp venom's; however, isolation and purification of the compounds can be problematical.
Attempts have been made to synthesise polyamine amides, for example as discussed in Pharmaceutical Sciences (1997), 3,223-233, Chem Letts (1993) 929-932, Chem Pharm Bull 44(5) 972-979 (1996) and by I.R. March and M. Bradley in Tetrahedron 1997, Vol 53, pages 17317 to 34. In the latter reference, a protected polyamine is prepared in solution and is then attached to a resin and used in a solid phase process. However, the solution preparation is hard, tedious and time-consuming and it is difficult to prepare polyamines in a parallel manner. Consequently, desired amines tend to be made one at a time, using the known art. It is an object of the present invention to provide an advantageous process for preparation of symmetrical and unsymmetrical polyamines.
According to a first aspect of the invention, there is provided a process for preparing a polyamine compound which includes a step (a) of treating a compound which incorporates a moiety of formula:
SS-NR-RC-NH- I
with a compound which incorporates a moiety of formula:
-NR1-Rb-L II
and optionally derivatising the product of the reaction, wherein SS represents a solid support and linking means for linking the group -NR- of moiety I to the support, R represents a hydrogen atom or an optionally-substituted alkyl or aryl group, R1 represents a hydrogen atom or an optionally-substituted alkyl or aryl group, Rb and Rc each independently represents an optionally-substituted alkylene or alkenylene group and L represents a leaving group.
Unless otherwise stated in this specification, where any group is stated to be optionally-substituted, it may be substituted by one or more substituents. Suitably, it may be substituted by up to 4, preferably up to 3, more preferably up to 2, especially up to 1 substituent. Unless otherwise stated in this specification, where any group is stated to be optionally-substituted, optional substituents may be selected from halogen (preferably fluorine, chlorine or bromine) atoms and optionally substituted, preferably unsubstituted, alkyl, acyl, aryl, nitro, cyano, alkoxy, alkoxyalkyl, hydroxy, amino, alkylamino (including dialkylamino) , sulphinyl, alkylsulphinyl, carbamoyl (including alkylcarbamoyl and dialkylcarbamoyl) , sulphonyl, alkylsulphonyl, sulphonate, amido, alkylamido, alkoxycarbonyl, halocarbonyl (especially chlorocarbonyl) , haloalkoxy, and haloalkyl (especially fluoroalkyl or chloroalkyl) , groups.
Unless otherwise stated in this specification, an alkyl, alkenyl, alkylene or alkenylene group may have up to 12, suitably up to 10, preferably up to 8, more preferably up to 6, especially up to 4, carbon atoms.
Unless otherwise stated in this specification, an aryl group is suitably an aromatic or heteroaromatic group which preferably has 6 to 10 ring atoms and, more preferably, has 6 or 10 ring atoms. Examples of aromatic groups include phenyl, 1-naphthyl and 2-naphthyl groups of which the phenyl group is preferred. Heteroaromatic groups may include one or more 0, N or S atoms or combinations thereof.
The process suitably produces a compound which incorporates a moiety: WO 00/35941 _- Δ4 _- PCT/GB99/01719
which may subsequently be optionally derivatized and/or a compound prepared may be detached from said SS moiety and/or said compound prepared may be optionally derivatized after detachment.
Preferably, R represents a hydrogen atom or an optionally-substituted, preferably an unsubstituted, alkyl group. More preferably, R represent a hydrogen atom.
Rb and Rc may independently have up to 10, suitably up to 8, preferably up to 6, more preferably up to 4, carbon atoms in a straight chain. Rb and Rc may have the same number of carbon atoms in a straight chain in which case compounds which include moiety III (and compounds moieties produced in downstream processes) may be symmetrical polyamines. However, Rb and Rc may have a different number of carbon atoms in a straight chain in which case compounds which include moiety III (and compounds/moieties produced in downstream processes) may be unsymmetrical polyamines. Unsymmetrical polyamines can be quite difficult to prepare by known processes; however, the process described herein can relatively easily be used to make such compounds. Preferably, R and Rc independently have 3 or 4 carbon atoms in a straight chain. More preferably, Rc has 4 carbon atoms and Rb has 3 carbon atoms in a straight chain. Rb and Rc may independently be optionally substituted by 1 or 2 optionally-substituted, preferably unsubstituted, alkyl groups, wherein each alkyl group suitably has 1 to 3 carbon atoms.
R1 suitably represents a hydrogen atom or a Cι-ιo, preferably Cι-8, more preferably Cι_6, especially Cι-4, alkyl group or an aryl group, said alkyl or aryl group being optionally-substituted, preferably by one or more substituents selected from halogen atoms, amino groups, alkylamino groups, dialkylamino groups, cyano groups, hydroxy groups, alkyl groups (except when the substituted group is alkyl) , aryl groups, carbamoyl groups, alkylcarbamoyl groups, dialkylcarbamoyl groups and carboxy groups and esters thereof.
Suitably, in said moiety II (and suitably in other moieties which include R1) , R1 represents a hydrogen atom or an optionally-substituted, preferably an unsubstituted, alkyl or aryl group. Preferably, R1 represents a hydrogen atom or an optionally-substituted alkyl group.
Said moiety of formula I may be part of a structure of formula:
SS-NR-RC-NHP1 IV
wherein P1 represents a protecting/activating group. P1 is preferably an electron-withdrawing group. It is preferably adapted to increase the acidity of the hydrogen atom of the group -NHP1. P1 preferably forms a sulphonamide group with moiety I. Thus, P1 preferably represents a moiety: -SO2-X1 V
wherein X1 represents an optionally-substituted aryl, especially phenyl, group. Said optionally-substituted aryl group may include one or more substituents. Preferred substituents are electron-withdrawing groups. A nitro group is a preferred optional substituent. A 4- nitro or a 2,4-nitro is especially preferred. Preferably, X1 represents a di-nitrophenyl group.
The mechanism of the reaction of moieties I and II is believed to involve attack of the nucleophilic nitrogen atom of moiety -NH- of moiety I with a carbon atom adjacent to leaving group L in moiety II. L is preferably an electron-withdrawing group. Consequently, the leaving group L is displaced.
L may need to be activated to act as a leaving group in the reaction. L may be any leaving group which may be electronegative and/or be capable of functioning in the mechanism referred to. L may be a halogen atom, preferably a bromine or chlorine atom, especially a bromine atom, or a hydroxy group. The ability of the hydroxy group to act as a leaving group may be caused and/or enhanced by other reagents used in the reaction.
Said moiety of formula II may be part of a structure of formula:
P2NRX-Rb-L VI wherein P2 represents a protecting group. Preferred protecting groups include N-l- (4, 4-dimethyl-2, 6- dioxocyclohex-1-ylidene) ethyl and Triethlsilyloxycarbonyl (TEOC) . The former is preferred.
Preferably, SS represents a solid support resin which includes linking means. Said linking means may include a -O-CO- moiety, the carboxy end of which is suitably bonded to the nitrogen atom of the moiety -NR- of moiety I. The alkoxy end of the -0-CO- moiety may be bonded to the resin by suitable means which is preferably an alkylene group, especially a -CH2- group. Said solid support resin may be any suitable resin, for example a polystyrene resin. Suitably, the linking means is a Wang linker.
In Step (a) , swollen resin of formula I (which may suitably be swollen in anhydrous tetrahydrofuran) , triphenylphosphine and a said compound which incorporates moiety II (especially compound VI) may be stirred together and, subsequently, a coupling agent, suitably diethylazodicarboxylate, is added, slowly. The mixture may be stirred for about 12 hours, filtered, washed and dried. The product of the reaction suitably incorporates moiety III and is suitably protected by groups P2 and P1 and is, therefore, of formula:
Said compound VI may be prepared by a reaction known to a person skilled in the art, wherein P2 is a protecting group.
Said compound IV may be prepared in a step (-b) which comprises reaction of a compound of general formula:
SS-NR-RC-NH2 VIII
with a compound of formula P1---2 wherein L2 is a leaving group, especially a chlorine atom. The reaction is preferably carried out in the presence of a base, for example 2,6-lutidine and in an organic solvent.
Said compound of formula VIII may be prepared in a step (-c) by reaction of a compound of formula
HRN-RC-NH2 IX
with a structure SS-L3 wherein L3 represents a leaving group which may include an imidazole moiety.
Compound VII and/or said compound incorporating moiety II can readily be derivatised to produce a wide range of compounds, suitably in a parallel array or combinatorial chemistry technique. In a first embodiment, compound VII and/or said compound incorporating moiety III may be treated with a further compound which incorporates a moiety of formula II (which moiety may include R1, Rb and L which are the same as or different to such groups used in Step (a) ) as described above thereby to prepare a compound which incorporates the moiety
or is of formula
wherein Rb(2), Rx(2) and P2(2) may be any group described herein for Rb, R1 and P2 respectively except that they may be the same or different to groups Rb and R1 used in Step (a) and P2 as described above.
In the derivatisation reaction of the first embodiment, said compound of formula VII may be reacted to remove P1 and replace it with, for example another protecting group (e.g. Boc) and P2 may be removed and replaced with a protecting/activating group of type P1 discussed above. The derivatised compound VII prepared may then be treated, for example with a structure of formula:
P2NR1(2)-Rb(2)-L
wherein P2 and L are as described above (although they could be different from P2 and L used in Step (a) ) . The reaction may be carried out under conditions as described above for Step (a) .
The derivatisation of the first embodiment may be further repeated to add successive groups -NR1 (3) -Rb(3) - etc.
Compound VII (or derivatives thereof prepared as described in said first embodiment) may be derivatized by a range of compounds, for example amino acids, may be coupled to moiety -NR1- (or -NR1 (2), -NR1 (3) if provided) , thereby replacing protecting group P2 and, in turn, other compounds, for example further amino acids, may be coupled to said compounds initially coupled to moiety -NR1- (or -NR1 (2), -NR1 (3), if provided) and/or derivatisation reactions effected. Further coupling reactions may also be effected by techniques known to those skilled in the art.
In general terms, a suitably deprotected compound VII and/or said compound incorporating moiety III may be treated with a first reagent (which may be protected) to replace group P2 in compound VII with a residue of said first reagent. The product (or a derivative), suitably deprotected, may be treated with a second reagent (which may be protected) so that said second reagent becomes bonded to a said residue of said second reagent. Such treatments may be repeated to react further reagents with the derivative of compound VII.
Suitably, said first reagent is di-functional. Said first reagent preferably includes an aryl group (or a precursor thereof) . Said first reagent preferably includes an amine group (or a precursor thereof) . Thus, suitably said first reagent (and a or any subsequent reagent) is an amino acid (or a precursor thereof, for example a protected version or derivative thereof) .
Suitably, said second reagent is di-functional. Said second reagent preferably includes an aryl group (or a precursor thereof) . Said second reagent preferably includes an amine group (or a precursor thereof) . Thus, suitably said second reagent is an amino acid (or a precursor thereof, for example a protected version or derivative thereof) . Further reagents which may be reacted with said second reagent may have any feature of said second reagent as described above.
More specifically, said compound of formula VII may be reacted in a step (b) to substitute the group P1 with another group which may be another protecting group P3 or an electrophilic reagent. Group P3 may be an acyl, -Boc, alkyl, or sulphonyl group. Thus, the product of step (b) may be a compound of formula
Protecting group P2 may next be removed from compound
(X) in a step (c) so that P2 is replaced by a hydrogen atom (such a compound being referred to as compound XI) .
Step (c) may involve reaction in hydrazine and an organic solvent or may involve any suitable deprotection reaction.
Next, in Step (d) , a compound may be coupled to the free -NH2 group of compound XI. For example, an amino acid, suitably an amino acid which is protected by a protecting group orthogonal to the group binding portions of compound X to the solid support of SS, such as an Fmoc protected amino acid (i.e. "Fmoc AA") , may be coupled to said free -NH2 group. Suitably, an amino acid selected from those shown in Summary 1 or Summary 2 hereinafter, especially those in Summary 1, may be coupled to said group. Thereafter, other compounds, for example other amino acids, may be coupled, for example to the aforementioned amino acid, in order to produce more complex compounds using procedures know to those skilled in the art. Suitably, an amino acid selected from those shown in Summary 1 or Summary 2 hereinafter, especially those in Summary 2, may be coupled.
Subsequently, the desired compound prepared may be cleaved from the resin and/or optionally derivatised as may be desired.
Such a compound may incorporate a moiety
Preferably such a compound is of general formula
wherein A1 is a substituent group which may comprise one or more optionally derivatised amino acid residues or is a salt of the aforementioned compound.
More preferably, such a compound may be of formula
wherein R, Rc, Rb and R1 are as described in any statement herein; W is a hydrogen atom or an optionally- substituted, preferably unsubstituted, alkyl or aryl group; Z is an amino acid residue, especially an aromatic amino acid residue; n is zero or a positive integer, preferably in the range 0-10, more preferably 0-4, especially 0 to 1; R2 and R3 are the same or different from each other and each represents a hydrogen atom or a group of formula R6, R6CO-, R6OCO- or R6NHCO- where R6 represents an optionally-substituted alkyl group, suitably a Ci-io, preferably a Ci-e, more preferably a Ci-β, especially a Cι- , alkyl group, or an optionally- substituted aryl group, wherein preferred optional substituents of said alkyl and aryl groups are selected from halogen atoms, amino groups, alkylamino groups, dialkylamino groups, cyano groups, hydroxy groups, alkyl groups (except when the substituted group is alkyl) , aryl groups, carbamoyl groups, alkylcarbamoyl groups, dialkylcarbamoyl groups and carboxy groups and esters thereof; Ra represents an optionally-substituted straight or branched chain alkylene or alkenylene group, preferably an alkylene or alkenylene group having 1 to 6 carbon atoms each optionally-substituted by from 1 to 4 alkyl groups each having from 1 to 3 carbon atoms; and Q represents an amidino group, a cyano group or a group of formula XYN-, wherein X and Y are the same or different, and each may represent a hydrogen atom, an alkyl group, (suitably a Ci-io, preferably a Cι_8, more preferably a Cι-6, especially a Ci_4 alkyl group) or a simple heteroatom-containing group or, together with the nitrogen atom to which they are attached, form a nitrogen-containing heterocyclic group.
The process described according to said first aspect may be used to prepare any of the polyamine compounds described in any of the documents cited in the introduction of this specification; and any of the polyamine compounds described in PCT/GB89/03775 and the polyamine compounds described in each of the aforementioned documents are incorporated herein by reference. According to a second aspect of the invention, there is provided a process for preparing a plurality of different polyamine compounds which includes a step of:
(a) selecting a plurality of different compounds of general formula I or a plurality of different compounds of formula II or a plurality of different compounds of both formulas I and II and reacting compounds of formula I with compounds of formula II, for example in a combinatorial or parallel array technique, followed by optional derivatisation, thereby to prepare a plurality of different polyamine compounds; OR
(b) derivatising a product of a reaction of a compound of general formula I with a compound of general formula II with a plurality of different compounds, followed by optional derivatisation of the product thereof, thereby to prepare a plurality of different polyamine compounds.
According to a third aspect of the invention, there is provided a library of compounds prepared in a process according to said second aspect.
According to a fourth aspect of the invention, there is provided a product of a process according to said first or second aspect.
According to a fifth aspect of the invention, there is provided any novel intermediate described in any statement herein.
Any feature of any aspect of any invention or embodiment described herein may be combined with any feature of any aspect of another invention described herein.
Specific embodiments of the invention will now be described, by way of example. In the Examples, the following abbreviations are used:
Arg arginine;
Boc t-butoxycarbonyl;
DCM dichloromethane
Dde N-l, 4 (4, 4-dimethyl-2, 6-dioxocyclohex-l- ylidine) ethyl; DEAD diethyl azodicarboxylate; DIC di-isopropylcarbodiimide; DMF dimethylformamide; Fmoc N-fluorenylmethoxycarbonyl; HOBt Nl-hydroxybenzotriazole; Lys lysine; Pbf 2,2,4, 6, 7-pentamethyldihydrobenzofuran-5- sulfonyl; Phe phenylalanine; RP-HPLC reverse phase high performance liquid chromatography; THF tetrahydrofuran; TFA trifluoracetic acid; TBTU 2 (lH-benzotriazole-1-yl) -1,1, 3,3- tetramethyluronium tetrafluoroborate TEOC 2- (Trimethylsilyl) ethoxycarbonyl. Example 1 - Preparation of Arginine-L-phenylalanine- spermidine - an unsymmetrical polyamine.
Wang resin (0.03 mmol, 50 mg) was swollen in anhydrous tetrahydrofuran (1.0 ml) and carbonyl diimidazole ( 4 equivalents, 0.12 mmol, 19 mg) was added. The resulting mixture was then stirred at ambient temperature for 16 hours, after which it was filtered and washed with tetrahydrofuran, ethanol and dichloromethane. The resin was then dried in vaci-o.
The resin was re-swollen in anhydrous dichloromethane (1.0 ml), and 1, 4-diaminobutane (10 equivalents, 0.3 mmol, 25 mg) were added. The resulting mixture was stirred for 2 hours and then filtered and washed (dimethylformamide, methanol, dichloromethane) , after which it was dried in vacuo.
The resin was again swollen in anhydrous dichloromethane (1.0 ml), and 2,6-lutidine (5 equivalents, 0.15 mmol, 16 mg) were added, followed by the careful addition of 2, 4-dinitrobenzenesulfonyl chloride (4 equivalents, 0.12 mmol, 32 mg) . The mixture was stirred under an inert atmosphere for 2 hours and then washed (dimethylformamide, methanol, dichloromethane) and dried in vacuo.
The resulting resin was then swollen in anhydrous tetrahydrofuran (1.0 ml) and triphenylphosphine (4 equivalents, 0.12 mmol, 32 mg) . Dde-protected aminoalcohol (4 equivalents, 0.12 mmol, 29 mg) (prepared as described below) were added and dissolved with stirring. Diethyl azodicarboxylate (4 equivalents, 0.12 - ID —
mmol, 21 mg) was added dropwise and the mixture was stirred for 12 hours and then filtered and washed (dimethylformamide, methanol, dichloromethane) . It was then dried in vacuo.
The resin was then swollen in dichloromethane (1.0 ml), and propylamine (5 equivalents, 0.15 mmol, 13 mg) was added. The mixture was then stirred for 1 hour after which it was filtered and washed (dimethylformamide, methanol, dichloromethane) and then dried in vacuo.
The resin was again swollen in dichloromethane (1.0 ml), and di-t-butyl dicarbonate (10 equivalents, 0.3 mmol, 33 mg) and N,N-dimethylaminopyridine (5 mol%, 0.0015 mmol, 0.2 mg) were added, and the mixture was stirred for 16 hours. The resin was then filtered and washed (dimethylformamide, methanol, dichloromethane) , and then dried in vacuo.
The resin was then stirred in 2% hydrazine hydrate/dimethylformamide (1.0 ml) for 1 hour and then washed (dimethylformamide, methanol, dichloromethane) , after which it was dried in vacuo.
Fmoc-Phe-OH (4 equivalents, 0.12 mmol, 46 mg) , TBTU (4 equivalents, 0.12 mmol, 39 mg) and diisopropylethylamine (8%, 0.48 mmol, 62mg) were dissolved in anhydrous dimethylformamide (1.0 ml), and the mixture was added to the resin. The whole was then stirred for 12 hours, and then filtered and washed (dimethylformamide, methanol, dichloromethane) and dried in vacuo. To the resin was added 20% piperidine/dimethylformamide (1.0 ml) and the mixture was stirred for 0.5 hour. It was then filtered and washed
(dimethylformamide, methanol, dichloromethane) and then dried in vacuo.
Boc-Arg(Pbf) -OH (4 equivalents, 0.12 mmol, 63 mg) , TBTU (4 equivalents, 0.12 mmol, 39 mg) , and diisopropylethylamine (8 equivalents, 0.48 mmol, 62 mg) were dissolved in dimethylformamide (1.0 ml) and the mixture was added to the resin. The whole was then stirred for 12 hours and then filtered and washed
(dimethylformamide, methanol, dichloromethane) . It was then dried in vacuo.
50%TFA/45%dichloromethane/2.5%H20/2.5% triisopropylsilane (1.0 ml) was added to the resin and the mixture was stirred for 1 hour. The resin was filtered and washed with dichloromethane (1.0 ml) and the filtrate was concentrated in vacuo. The resulting viscous yellow oil was triturated with anhydrous diethyl ether (3x2 ml) to yield the title compound as shown below as its tetrakis TFA salt (19 mg, 70%) :
Analysis :
LCMS - 90% (ELS detection) . M/z 449 (ES+) NMR:- H NMR was found to be in accordance with the above structure
In the above described process, the following Dde protected aminoalcohol was used:
The Dde protected aminoalcohol was prepared as follows: To a solution of 3-amino-l-propanol (1.5 g, 20 mmol) in ethanol was added 2-acetyl dimedone (1.1 equivalents, 22 mmol, 4.0 g) and the mixture was heated to
50°C for 1 hour. The resulting solution was concentrated in vacuo to yield a red crystalline solid that was triturated with hexane to afford an off-white solid
(4.74g, 95%).
Examples 2 - Preparation of other polyamines
Polyamines having the general structure :
[Porti n2HPortion1 N^N^ N
H H
E-I
wherein Portions 1 and 2 are amino acid residues as described hereinafter and wherein n represents 3 or 4 and m represents 4 were prepared using the following general method which is summarised in Scheme 1. Step 1
Wang resin (0.03 mmol) was swollen in anhydrous THF (1.0 ml) and carbonyl diimidazole (4 eq, 0.12 mmol) added portionwise. The resulting mixture was stirred at ambient temperature for 16 hours then filtered and washed with THF, Et20 and DCM. The resin was then dried in vacuo (Step 1) .
Step 2
The resin was re-swollen in anhydrous DCM (1.0 ml) and a symmetrical diamine (NH2- (CH2)m-NH2) (10 eq, 0.3 mmol) added portionwise. The resulting mixture was stirred for
2 hours then filtered and washed (DMF, MeOH, DCM) then dried in vacuo.
Step 3
The resin was again re-swollen in anhydrous DCM (1.0 ml) and 2,6-lutidine (5 eq, 0.15 mmol) added followed by the careful addition of 2, 4-dinitrobenzenesulfonyl chloride (4 eq, 0.12 mmol). The mixture was stirred under an inert atmosphere for 2 hours then washed (DMF, MeOH, DCM) and dried in vacuo.
Step 4
The resulting resin was then swollen in anhydrous THF (1.0 mol) and triphenylphosphine (4 eq, 0.12 mmol), Dde- protected aminoalcohol (DdeHN- (CH2)n-OH) (4 eq, 0.12 mmol) were added and dissolved with stirring. Diethylazodicarboxylate (4 eq, 0.12 mmol) was added dropwise and the mixture stirred for 12 hours then filtered and washed (DMF, MeOH, DCM) then dried in vacuo.
Step 5
The resin was then swollen in DCM (1.0 ml) and n- propylamine (5 eq, 0.15 mmol) added and the mixture stirred for 1 hour then filtered and washed (DMF, MeOH, DCM) then dried in vacuo.
The resin was again swollen in DCM (1.0 ml) and di-t- butyldicarbonate (10 eq, 0.3 mmol) and N,N- dimethylaminopyridine (5 mol%, 0.0015 mmol) added and the mixture stirred for 16 hours. The resin was then filtered and washed (DMF, MeOH, DCM) then dried in vacuo.
Step 6
The resin was then stirred in 2% hydrazine hydrate/DMF (1.0 ml) for 1 hour then washed (DMF, MeOH, DCM) and dried in vacuo.
Step 7
The Fmoc derivatives of the amino acids shown in Summary 1 (wherein residues thereof are destined to become Portion 1 in the polyamines) were prepared (hereinafter referred to, generally, as "Fmoc AA1") . Then, Fmoc AA1 (4 eq, 0.12 mmol), TBTU (4 eq, 0.12 mmol) and diisopropylethylamine (8 eq, 0.48 mmol) were dissolved in anhydrous DMF (1.0 ml) and the mixture added to the resin. The whole was then stirred for 12 hours then filtered and washed (DMF, MeOH, DCM) and dried in vacuo.
Step 8
To the resin was added 20% piperidine/DMF (1.0 ml) and the mixture stirred for 0.5 hours then filtered and washed (DMF, MeOH, DCM) then dried in vacuo.
The Boc derivatives of the amino acids shown in Summary 2 (wherein residues thereof are destined to become Portion 2 in the polyamines) were prepared (hereinafter referred to, generally, as "Boc AA") . Then, Boc AA (4 eq, 0.12 mmol), TBTU (4 eq, 0.12 mmol), and diisopropylethylamine (8 eq, 0.48 mmol) were dissolved in DMF (1.0 ml) and the mixture added to the resin. The whole was then stirred for 12 hours then filtered and washed (DMF, MeOH, DCM) then dried in vacuo.
Step 9
50%TFA/45%DCM/2.5%H2O/2.5% triisopropylsilane (1.0 ml) was added to the resin and the mixture stirred for 1 hour to remove the compound from the resin (Step 9) . The resin was filtered and washed with DCM (1.0 ml) and the filtrate concentrated in vacuo. The resulting viscous yellow oil was triturated with anhydrous diethylether (3x2 ml) to yield the required compound.
A wide range of compounds were prepared using the general method described and using the amino acids in Summary 1 to provide Portion 1 and the amino acids in Summary 2 to provide Portion 2. It will be appreciated that amino acid residues incorporated into compound E-I comprise the amino acids shown in Summary I and II but excluding hydrogen atoms from the -NH2 and -C02H groups.
Table 1 summarises a 4, 4-polyamine library prepared - that is, a library wherein n and m represent 4; the left column in the table details respective Portion l's (identified by their letters in Summary 1) used to prepare the compounds; and the top row details respective Portion 2's (identified by their numbers in Summary 2) used to prepare the compounds. Table 2 summarises a 3, 4-polyamine library - that is, wherein n represents 3 and m represents 4 with Portions 1 and 2 being identified as before.
In tables 1 and 2, each box in the table represents a particular compound prepared and the Mass Spec (ES+) and HPLC Retention Time in minutes are provided in each box (where available) .
Summary 1 - amino acids used to form "Portion 1" amino acid residues.
B
Hj COjH
F Portion 1 absent Summary 2 - amino acids used to form "Portion 2' amino acid residues.
00
TABLE 2 - 3, -Polyamine Library.
Wang resin
Step 7 Fmoc AA1
Step θ
acid side chain of AA1 acid side chain of AA2 Example 3 - Alternative reagent for Step 4
As an alternative to the use of Dde-protected aminoalcohols in Step 4, TEOC may be used.
Example 4 - Derivatives of polyamines
Derivatives of the amines prepared in Examples 1 and 2 may be prepared by reaction with a compound having an electrophilic specie such as an acid chloride, sulphonyl chloride etc. In a specific example, the starting material of Step 5 may be acylated, instead of using di-t- butyldicarbonate to give a Boc protecting group. Acylation may be carried out using a standard technique, using an acid chloride or another activated acid, to produce peptidomimetics . Sulphonyl chlorides may be used to sulphonylate amine groups to produce derivatives.
Example 5
Step 4 in Example 4 may be repeated more than once in order to add further moieties -NH-(CH2)n- to the polyamine chain. To this end, after Step 5 in Scheme 1, the Dde group may be removed and the resultant free amine group re-sulphonated in a process analogous to that described in Step 3. The re-sulphonated product may then be treated with a Dde-protected amine alcohol in a process analogous to that described in Step 4. Step 5 may be repeated. Subsequently, further moieties -NH-(CH2)n- may be added in the manner described or Step 6 and subsequent steps described may be carried out. Thus, the product of Step 6 may be of formula
wherein N is an integer of 1 or greater and wherein n may be the same or different for each repeat unit N.
The reader' s attention is directed to all papers and documents which are filed concurrently with or previous to this specification in connection with this application and which are open to public inspection with this specification, and the contents of all such papers and documents are incorporated herein by reference.
All of the features disclosed in this specification
(including any accompanying claims, abstract and drawings) , and/or all of the steps of any method or process so disclosed, may be combined in any combination, except combinations where at least some of such features and/or steps are mutually exclusive.
Each feature disclosed in this specification (including any accompanying claims, abstract and drawings), may be replaced by alternative features serving the same, equivalent or similar purpose, unless expressly stated otherwise. Thus, unless expressly stated otherwise, each feature disclosed is one example only of a generic series of equivalent or similar features.
The invention is not restricted to the details of the foregoing embodiment (s) . The invention extend to any novel one, or any novel combination, of the features disclosed in this specification (including any accompanying claims, abstract and drawings) , or to any novel one, or any novel combination, of the steps of any method or process so disclosed.

Claims

1. A process for preparing a polyamine compound which includes a step (a) of treating a compound which incorporates a moiety of formula:
SS-NR-RC-NH- I
with a compound which incorporates a moiety of formula:
-NR1-Rb-L II
and optionally derivatising the product of the reaction, wherein SS represents a solid support and linking means for linking the group -NR- of moiety I to the support, R represents a hydrogen atom or an optionally-substituted alkyl or aryl group, R1 represents a hydrogen atom or an optionally-substituted alkyl or aryl group, R and Rc each independently represents an optionally-substituted alkylene or alkenylene group and L represents a leaving group.
2. A process according to claim 1, wherein said process produces a compound which incorporates a moiety:
3. A process according to claim 1 or claim 2, wherein said moiety of formula I is part of a structure of formula:
SS-NR-RC-NHP1 IV
wherein P1 represents a protecting and/or activating group.
4. A process according to any preceding claim, wherein said moiety of formula II is part of a structure of formula:
P2NR1- b-L
wherein P2 represents a protecting group.
5. A process according to any preceding claim, wherein the product of the reaction of moieties of formula I and II is of formula
wherein P1 represents a protecting and/or activating group and P2 represents a protecting group.
6. A process according to any preceding claim, wherein the polyamine prepared by reacting moieties I and II and/or moiety III and/or moiety VII are derivatised in a subsequent process step.
7. A process according to claim 6, wherein derivatisation involves treatment with a first reagent in order to incorporate a residue of said first reagent into said polyamine.
8. A process according to claim 7, wherein said first reagent is difunctional.
9. A process according to claim 7 or claim 8, wherein said first reagent includes an amine group or a precursor of an amine group.
10. A process according to any of claims 7 to 9, wherein said first reagent is an amino acid or a precursor thereof.
11. A process according to any of claims 7 to 10, wherein said polyamine is derivatised with a second reagent.
12. A process according to any preceding claim, wherein R represents a hydrogen atom or an optionally-substituted alkyl group; R and Rc independently have up to 10 carbon atoms in a straight chain; R1 represents a hydrogen atom or an optionally-substituted Ci-io alkyl group or an optionally-substituted aryl group.
13. A process according to any preceding claim, wherein L is an electron-withdrawing group.
14. A process according to any preceding claim, wherein L represents a halogen atom or an hydroxy group.
15. A process according to any preceding claim, wherein the compound prepared in the process is of general formula
wherein A1 is a substituent group.
16. A process for preparing a plurality of different polyamine compounds which includes a step of:
(a) selecting a plurality of different compounds which include moiety I and/or a plurality of different compounds which include moiety II and reacting compound (s) of formula I with compound (s) of formula II, followed by optional derivatisation thereby to prepare a plurality of different polyamine compounds; OR
(b) derivatising a product of a reaction of a moiety I with a moiety II with a plurality of different compounds, followed by optional derivatisation of the product thereof, thereby to prepare a plurality of different polyamine compounds;
wherein moieties I and II are as described in any preceding claim.
17. A library of compounds prepared in a process according to claim 16.
18. A product of a process described in any of claims 1 to 16.
19. Any novel intermediate of a process described in any of claims 1 to 16.
EP99936759A 1998-12-16 1999-06-16 Combinatorial process for preparing polyamines Withdrawn EP1144434A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
WOPCT/GB98/03775 1998-12-16
PCT/GB1998/003775 WO1999031049A1 (en) 1997-12-16 1998-12-16 Neuroprotective agents
PCT/GB1999/001719 WO2000035941A2 (en) 1998-12-16 1999-06-16 Combinatorial process for preparing polyamines

Publications (2)

Publication Number Publication Date
EP1144434A2 true EP1144434A2 (en) 2001-10-17
EP1144434A3 EP1144434A3 (en) 2002-05-29

Family

ID=10827438

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99936759A Withdrawn EP1144434A3 (en) 1998-12-16 1999-06-16 Combinatorial process for preparing polyamines

Country Status (3)

Country Link
EP (1) EP1144434A3 (en)
CA (1) CA2355880A1 (en)
WO (1) WO2000035941A2 (en)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU758570B2 (en) * 1997-07-15 2003-03-27 Mediquest Therapeutics, Inc. Novel polyamine analogues as therapeutic and diagnostic agents

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0035941A3 *

Also Published As

Publication number Publication date
CA2355880A1 (en) 2000-06-22
EP1144434A3 (en) 2002-05-29
WO2000035941A2 (en) 2000-06-22
WO2000035941A3 (en) 2001-10-04

Similar Documents

Publication Publication Date Title
RU2715233C2 (en) Method of producing nitrogen mustard derivatives
Myers et al. Facile incorporation of urea pseudopeptides into protease substrate analogue inhibitors
CN114040920A (en) Method for producing peptide compound, protecting group-forming reagent, and fused polycyclic aromatic hydrocarbon compound
US7067698B2 (en) Bi-directional synthesis of oligoguanidine transport agents
WO2021177336A1 (en) Peptide and cell membrane permeation agent
AU2006318131B2 (en) Compounds for the inhibition of apoptosis
Ricardo et al. On the scope of the double Ugi multicomponent stapling to produce helical peptides
Vandersteen et al. Liquid-phase combinatorial synthesis: in search of small-molecule enzyme mimics
US6872825B2 (en) Peptide β-turn mimetic compounds and processes for making them
EP1144434A2 (en) Combinatorial process for preparing polyamines
CA2922332A1 (en) A photolabile linker for the solid-phase synthesis of hydrazides and pyranopyrazoles
Busnel et al. Synthesis of Fmoc-protected aza-β3-amino acids via reductive amination of glyoxylic acid
JP5947821B2 (en) Method for producing cereulide and derivatives thereof, intermediate for producing cereulide and cereulide derivatives
Plöger et al. Improved Large‐Scale Liquid‐Phase Synthesis and High‐Temperature NMR Characterization of Short (F‐) PNAs
TWI772159B (en) Method of synthesizing dendrimeric amphiphile
Ferrer‐Gago et al. Synthesis of C‐terminal glycine‐rich o‐aminoanilide peptides without overacylation for use in benzotriazole‐mediated native chemical ligation
Pinto et al. Straightforward, racemization-free synthesis of peptides with fairly to very bulky di-and trisubstituted glycines
WO2023023889A1 (en) Method of synthesizing dendrimeric amphiphile
US8124756B2 (en) Method of preparing 5′-amino-linker oligonucleotides derivatives and analogous 5′-labeled-linker oligonucleotides therefrom
CZ20022110A3 (en) Peptide beta-rotating mimetic compounds and process of their preparation
EP4247798A1 (en) Synthesis of prostate specific membrane antigen (psma) ligands
EP4247785A1 (en) Synthesis of prostate specific membrane antigen (psma) ligands
WO2023102255A1 (en) Peptide-encoded libraries of small molecules for de novo drug discovery
US6664410B1 (en) Solid phase nitrile synthesis
Chulin et al. Synthesis of 10‐and 9‐membered dilactams derived from aspartic and glutamic acids

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010627

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB IE IT LI NL SE

XX Miscellaneous

Free format text: DERZEIT SIND DIE WIPO-PUBLIKATIONSDATEN A3 NICHT VERFUEGBAR.

PUAK Availability of information related to the publication of the international search report

Free format text: ORIGINAL CODE: 0009015

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB IE IT LI NL SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20050101